Maple LEAP-2 (liver-expressed antimicrobial peptide-2) is an endogenous peptide that functions as a competitive antagonist and inverse agonist at the growth hormone secretagogue receptor 1a (GHSR1a), directly opposing the actions of ghrelin. Preclinical research demonstrates that LEAP-2 suppresses ghrelin-stimulated growth hormone secretion, reduces food intake in rodent models, and modulates glucose homeostasis through GHSR1a-dependent mechanisms. As interest in ghrelin system pharmacology intensifies — particularly in metabolic disease research — LEAP-2 has emerged as a compelling counter-regulatory peptide with distinct receptor dynamics from classical ghrelin antagonists.
For research purposes only. Not for human consumption.
What Is LEAP-2? Discovery and Structural Profile
LEAP-2 was first characterized in 2003 by Henriques et al. as a cationic antimicrobial peptide isolated from human blood filtrate. Its initial characterization focused on its disulfide-bridged structure and broad-spectrum antimicrobial activity, placing it in the same structural family as defensins and hepcidin. For roughly 15 years, LEAP-2 attracted limited attention beyond its antimicrobial properties. That changed decisively in 2019 when Mani et al. published a landmark study in Cell Metabolism demonstrating that LEAP-2 is a high-affinity endogenous ligand for GHSR1a — the same receptor activated by ghrelin — but with opposing functional consequences.
The mature human LEAP-2 peptide is 40 amino acids in length, though a truncated form comprising the first 14 residues (LEAP-2[1-14]) retains full GHSR1a binding activity and represents the pharmacologically active fragment most commonly used in preclinical research. The peptide is primarily produced in the liver and small intestine, with hepatic expression being substantially higher than intestinal output under basal conditions. Plasma LEAP-2 concentrations in rodents are hormonally regulated: fasting dramatically suppresses LEAP-2 levels while feeding and elevated glucose restore them. This inverse relationship with nutritional state — mirroring but opposing ghrelin’s pattern — suggests the two peptides form a coordinated regulatory axis at GHSR1a.
GHSR1a Pharmacology: LEAP-2 as Antagonist and Inverse Agonist
GHSR1a is unusual among G protein-coupled receptors in that it exhibits constitutive activity: even in the absence of a ligand, the receptor maintains approximately 50% of its maximal signaling capacity through spontaneous Gq protein coupling and inositol phosphate turnover. Ghrelin binding increases this activity to near-maximal levels, driving phospholipase C activation, intracellular calcium mobilization, and downstream effects on appetite, growth hormone (GH) release, and glucose metabolism.
The Mani et al. (2019) Cell Metabolism study established that LEAP-2 acts as both a competitive antagonist and an inverse agonist at GHSR1a. In competitive antagonism mode, LEAP-2 occupies the orthosteric binding pocket and blocks ghrelin from engaging the receptor. As an inverse agonist, LEAP-2 additionally suppresses the receptor’s constitutive basal activity below baseline — a pharmacologically meaningful distinction because it means LEAP-2 inhibits GHSR1a signaling even in the absence of circulating ghrelin. In binding assays, LEAP-2[1-14] displaced [125I]-ghrelin from GHSR1a-expressing cells with an IC50 of approximately 14.3 nM, demonstrating high-affinity competitive binding at the receptor’s endogenous ligand site.
Radioligand binding competition studies further confirmed that LEAP-2 does not activate the receptor at any tested concentration — it produces no measurable inositol phosphate accumulation on its own, and in the presence of ghrelin, it dose-dependently reduces ghrelin’s stimulatory effect on IP1 production. This clean pharmacological profile, with no partial agonism, distinguishes LEAP-2 from some synthetic GHSR1a modulators that exhibit biased or partial agonist activity depending on the signaling pathway examined.
Key Research Findings
- LEAP-2[1-14] bound GHSR1a with IC50 ~14.3 nM in competitive radioligand displacement assays, confirming high-affinity orthosteric binding (Mani et al., 2019, Cell Metabolism)
- Subcutaneous LEAP-2 administration (1 and 3 nmol) blocked ghrelin-induced feeding in fasted mice within 30 minutes post-injection; ghrelin-treated controls showed a 2.3-fold increase in food intake vs. vehicle, which LEAP-2 fully suppressed at 3 nmol (Mani et al., 2019)
- Central (intracerebroventricular) LEAP-2 injection in rats suppressed spontaneous nocturnal food intake by approximately 30% compared to vehicle controls at a 1 nmol dose (Mani et al., 2019)
- In LEAP-2 knockout mice, ghrelin-induced GH secretion was amplified 1.8-fold compared to wild-type littermates, demonstrating that endogenous LEAP-2 tonically restrains ghrelin-driven GH release under physiological conditions
- Plasma LEAP-2 concentrations were significantly suppressed by 24-hour fasting (reduced by approximately 60% in C57BL/6 mice) and rapidly restored by glucose gavage, establishing its nutritional regulation pattern (Ge et al., 2018, Diabetes)
- High-fat diet feeding in rodents elevated plasma LEAP-2 concentrations significantly above chow-fed controls (approximately 2.1-fold), while simultaneously suppressing ghrelin, suggesting a coordinated response to nutrient surfeit
Regulation of GH Secretion: Restraining the Somatotropic Axis
One of the most well-characterized functions of LEAP-2 in preclinical models is its capacity to attenuate ghrelin-stimulated GH secretion from anterior pituitary somatotrophs. GHSR1a is highly expressed in somatotrophs, and ghrelin is one of the most potent endogenous GH secretagogues identified to date. The physiological relevance of LEAP-2 as a counter-regulatory check on this axis was demonstrated in LEAP-2 knockout experiments: mice lacking LEAP-2 showed exaggerated GH pulse amplitude in response to exogenous ghrelin administration, confirming that endogenous LEAP-2 normally limits the magnitude of ghrelin-driven GH release.
This finding has implications for understanding why fasting — which suppresses LEAP-2 while elevating ghrelin — produces such robust GH secretory bursts. The reciprocal regulation of ghrelin and LEAP-2 during nutrient deprivation appears to function as a coordinated permissive mechanism: falling LEAP-2 removes tonic GHSR1a antagonism at the same time rising ghrelin provides maximal agonist stimulation, resulting in amplified GH secretion that supports protein conservation and lipid mobilization during caloric restriction. When feeding is restored, rising LEAP-2 reasserts receptor-level inhibition and dampens GH pulsatility toward baseline.
Metabolic Research: Appetite, Glucose, and Adiposity
Beyond GH axis regulation, LEAP-2 research has focused heavily on appetite and metabolic homeostasis. Ghrelin is the only identified circulating peptide that consistently increases food intake when administered peripherally, and its orexigenic effect is entirely GHSR1a-dependent. LEAP-2’s ability to block this effect has generated significant interest as a tool for dissecting the ghrelin signaling axis in obesity and metabolic disease research models.
In acute feeding studies, subcutaneous LEAP-2 administration in fasted mice dose-dependently reduced the hyperphagia induced by exogenous ghrelin, with full suppression of the orexigenic response at 3 nmol doses. Importantly, LEAP-2 did not significantly alter basal food intake in fed, non-ghrelin-treated mice, suggesting its anorectic effect operates primarily through ghrelin antagonism rather than through independent appetite suppression pathways. This selectivity is pharmacologically relevant: it implies that LEAP-2’s efficacy as a research tool is contingent on the ghrelin-activation state of the animal, making it particularly useful in paradigms where ghrelin tone is elevated (fasting, caloric restriction, post-surgical states).
Ge et al. (2018) in Diabetes expanded the metabolic profile of LEAP-2 by examining its regulation in the context of obesity and insulin resistance. In diet-induced obese mice, plasma LEAP-2 was elevated relative to lean controls, while ghrelin was suppressed — a pattern consistent with LEAP-2 serving as a postprandial and nutrient-status sensor at the ghrelin receptor. The study also found that LEAP-2 expression was significantly elevated in fatty liver disease models, raising the question of whether hepatic LEAP-2 overproduction in obesity contributes to the attenuated ghrelin responses commonly observed in obese individuals. The mechanistic underpinning, however, requires further clarification: whether elevated LEAP-2 in obesity is cause, consequence, or compensatory remains an active area of preclinical investigation.
Central Nervous System Actions and Hypothalamic GHSR1a
GHSR1a expression in the central nervous system is concentrated in the hypothalamic arcuate nucleus (ARC), where agouti-related peptide (AgRP)/neuropeptide Y neurons express high receptor density and respond to ghrelin with increased orexigenic signaling. LEAP-2 crosses the blood-brain barrier poorly when administered peripherally, but central administration studies have clarified its intrinsic CNS pharmacology. Intracerebroventricular injection of LEAP-2 in rodents suppressed spontaneous nocturnal food intake — the period of maximal feeding activity in mice — at doses as low as 1 nmol, a finding consistent with direct hypothalamic GHSR1a antagonism.
Research using c-Fos immunohistochemistry as a neuronal activation marker found that central LEAP-2 reduced the number of activated AgRP neurons in the ARC following ghrelin challenge, providing histological evidence that LEAP-2’s appetite-suppressing effect involves direct inhibition of ghrelin-responsive orexigenic circuits. The peptide did not significantly activate anorexigenic pro-opiomelanocortin (POMC) neurons under the same conditions, suggesting its CNS effect is primarily receptor-blockade based rather than reflecting activation of parallel satiety pathways.
LEAP-2 as a Research Probe: Distinguishing Constitutive vs. Ligand-Driven GHSR1a Activity
One of LEAP-2’s most valuable research applications is as a pharmacological tool for separating constitutive from ghrelin-stimulated GHSR1a signaling. Because GHSR1a has substantial basal activity independent of ghrelin occupancy, experiments that use competitive ghrelin antagonists without inverse agonist activity leave this constitutive component intact. LEAP-2’s inverse agonist profile allows researchers to suppress total GHSR1a output — both ligand-driven and constitutive — enabling cleaner attribution of phenotypes to receptor signaling versus compensatory mechanisms.
This distinction is particularly relevant in interpreting results from GHSR1a knockout models, which eliminate both ligand-dependent and constitutive activity simultaneously. LEAP-2 treatment in GHSR1a-expressing animals provides a reversible, dose-titratable pharmacological analog of receptor knockout that preserves normal developmental receptor expression while acutely suppressing activity. The peptide is therefore used in experimental designs that require transient receptor silencing without the confounding variables introduced by germline or inducible knockout strategies.
Analytical Considerations for LEAP-2 Research
LEAP-2 contains two disulfide bonds in its full-length form that are critical for structural integrity and antimicrobial activity, though the pharmacologically active GHSR1a-binding fragment LEAP-2[1-14] lacks these bonds entirely and is a linear peptide. Researchers working with full-length LEAP-2 must confirm disulfide bond formation status via mass spectrometry, as reduced (free thiol) forms exhibit substantially different physicochemical properties. High-performance liquid chromatography (HPLC) with UV detection at 214 nm provides effective purity assessment for both fragments; reversed-phase C18 columns with acetonitrile-water gradients containing 0.1% trifluoroacetic acid are standard for this peptide class.
Storage of lyophilized LEAP-2 at -20°C under desiccated conditions is recommended to prevent methionine oxidation and non-specific thiol reactivity. Reconstitution in sterile physiological saline or 0.1% acetic acid followed by aliquoting and refreezing preserves peptide integrity over multiple experimental cycles. Independent third-party COA verification — including HPLC purity percentage and mass spectrometry identity confirmation — is the standard for research-grade material, as manufacturing process differences can produce variability in bioactive fragment composition that is not detectable by appearance alone. Maple Research Labs provides batch-specific certificates of analysis verified by Janoshik Analytical for all peptides in its research catalogue.
Positioning Within the Ghrelin Research Field
LEAP-2 occupies a unique position in the ghrelin system research landscape because it is endogenous, physiologically regulated, and pharmacologically distinguishable from synthetic GHSR1a antagonists such as [D-Lys3]-GHRP-6 and JMV 2959. While these synthetic tools have driven much of what is understood about GHSR1a physiology, their non-physiological structures introduce uncertainty about receptor interaction geometry that LEAP-2 avoids by engaging the orthosteric site through an evolved endogenous interface. This makes LEAP-2 a complementary rather than redundant addition to the ghrelin receptor pharmacology toolkit.
Ongoing research is examining whether LEAP-2 levels are dysregulated in clinical conditions characterized by ghrelin system imbalance, including anorexia nervosa, Prader-Willi syndrome, and post-bariatric surgery physiology, where ghrelin dynamics are markedly altered. Preclinical models of these conditions using LEAP-2 as a receptor probe may help clarify whether ghrelin overactivity or GHSR1a constitutive activity drives specific phenotypes — a question with direct relevance to understanding the receptor-level pharmacology of metabolic disease.
For researchers examining growth hormone secretagogue receptor biology, metabolic peptide signaling, or the counter-regulatory mechanisms that limit ghrelin action, LEAP-2 represents a well-characterized tool with a clean pharmacological profile and established preclinical precedent. Its nutritional regulation pattern, dual antagonist-inverse agonist receptor activity, and endogenous origin make it particularly suitable for experiments designed to interrogate the physiological boundaries of GHSR1a signaling.
Explore related research compound profiles including sermorelin, GHRP-6, and ipamorelin in the Maple Research Labs catalogue. For methodology, see our overview of COA verification standards and the full research peptide catalogue.
For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.
Want more research like this?
Weekly peptide study breakdowns. No spam. Unsubscribe anytime.